Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 135

1.

Application of a multi-state model to Evaluate Visit Burden and Patient Stability to Improve Sustainability of HIV Treatment in Zambia.

Roy M, Holmes C, Sikazwe I, Savory T, Mwanza MW, Bolton Moore C, Mulenga K, Czaicki N, Glidden DV, Padian N, Geng E.

Clin Infect Dis. 2018 Apr 7. doi: 10.1093/cid/ciy285. [Epub ahead of print]

PMID:
29635466
2.

Skating on thin ice: stimulant use and sub-optimal adherence to HIV pre-exposure prophylaxis.

Hojilla JC, Vlahov D, Glidden DV, Amico KR, Mehrotra M, Hance R, Grant RM, Carrico AW.

J Int AIDS Soc. 2018 Mar;21(3):e25103. doi: 10.1002/jia2.25103.

3.

Metabolic Effects of Pre-Exposure Prophylaxis with Co-Formulated Tenofovir Disoproxal Fumarate and Emtricitabine.

Glidden DV, Mulligan K, McMahan V, Anderson PL, Guanira J, Chariyalertsak S, Buchbinder SP, Bekker LG, Schechter M, Grinsztejn B, Grant RM.

Clin Infect Dis. 2018 Feb 3. doi: 10.1093/cid/ciy083. [Epub ahead of print]

PMID:
29415175
4.

Estimated mortality on HIV treatment among active patients and patients lost to follow-up in 4 provinces of Zambia: Findings from a multistage sampling-based survey.

Holmes CB, Sikazwe I, Sikombe K, Eshun-Wilson I, Czaicki N, Beres LK, Mukamba N, Simbeza S, Bolton Moore C, Hantuba C, Mwaba P, Phiri C, Padian N, Glidden DV, Geng E.

PLoS Med. 2018 Jan 12;15(1):e1002489. doi: 10.1371/journal.pmed.1002489. eCollection 2018 Jan.

5.

HIV sero disclosure among men who have sex with men and transgender women on HIV pre-exposure prophylaxis.

Hojilla JC, Mehrotra M, Truong HM, Glidden DV, Amico KR, McMahan V, Vlahov D, Chariyalertsak S, Guanira JV, Grant RM, For The iPrEx Study Team.

AIDS Care. 2018 Apr;30(4):466-472. doi: 10.1080/09540121.2017.1394437. Epub 2017 Oct 28.

PMID:
29082776
6.

HIV prevention trial design in an era of effective pre-exposure prophylaxis.

Cutrell A, Donnell D, Dunn DT, Glidden DV, Grobler A, Hanscom B, Stancil BS, Meyer RD, Wang R, Cuffe RL.

HIV Clin Trials. 2017 Nov-Dec;18(5-6):177-188. doi: 10.1080/15284336.2017.1379676. Epub 2017 Oct 17.

PMID:
29039265
7.

Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis.

Glidden DV, Mulligan K, McMahan V, Anderson PL, Guanira J, Chariyalertsak S, Buchbinder SP, Bekker LG, Schechter M, Grinsztejn B, Grant RM.

J Acquir Immune Defic Syndr. 2017 Oct 1;76(2):177-182. doi: 10.1097/QAI.0000000000001475.

PMID:
28639995
8.

Response to: A double-edged sword: does highly active antiretroviral therapy contribute to syphilis incidence by impairing immunity to Treponema pallidum?

Glidden DV, Mayer K, Grant RM.

Sex Transm Infect. 2017 Aug;93(5):313. doi: 10.1136/sextrans-2017-053212. Epub 2017 Apr 13. No abstract available.

PMID:
28408646
9.

Association Between a Virtual Glucose Management Service and Glycemic Control in Hospitalized Adult Patients: An Observational Study.

Rushakoff RJ, Sullivan MM, MacMaster HW, Shah AD, Rajkomar A, Glidden DV, Kohn MA.

Ann Intern Med. 2017 May 2;166(9):621-627. doi: 10.7326/M16-1413. Epub 2017 Mar 28.

PMID:
28346946
10.

The Causal Effect of Tracing by Peer Health Workers on Return to Clinic Among Patients Who Were Lost to Follow-up From Antiretroviral Therapy in Eastern Africa: A "Natural Experiment" Arising From Surveillance of Lost Patients.

Bershetyn A, Odeny TA, Lyamuya R, Nakiwogga-Muwanga A, Diero L, Bwana M, Braitstein P, Somi G, Kambugu A, Bukusi E, Hartogensis W, Glidden DV, Wools-Kaloustian K, Yiannoutsos C, Martin J, Geng EH; East Africa International Epidemiologic Databases to Evaluate AIDS (EA-IeDEA) Consortium.

Clin Infect Dis. 2017 Jun 1;64(11):1547-1554. doi: 10.1093/cid/cix191.

PMID:
28329184
11.

Differences in Cumulative Exposure and Adherence to Tenofovir in the VOICE, iPrEx OLE, and PrEP Demo Studies as Determined via Hair Concentrations.

Koss CA, Bacchetti P, Hillier SL, Livant E, Horng H, Mgodi N, Mirembe BG, Gomez Feliciano K, Horn S, Liu AY, Glidden DV, Grant RM, Benet LZ, Louie A, van der Straten A, Chirenje ZM, Marrazzo JM, Gandhi M.

AIDS Res Hum Retroviruses. 2017 Mar 2. doi: 10.1089/aid.2016.0202. [Epub ahead of print]

PMID:
28253024
12.

Limitations of using the Lorenz curve framework to understand the distribution of population viral load: authors' reply.

Christopoulos KA, Hartogensis W, Glidden DV, Pilcher CD, Gandhi M, Geng EH.

AIDS. 2017 Mar 13;31(5):742-743. doi: 10.1097/QAD.0000000000001407. No abstract available.

13.

Incorporation of the time aspect into the liability-threshold model for case-control-family data.

Cederkvist L, Holst KK, Andersen KK, Glidden DV, Frederiksen K, Kjaer SK, Scheike TH.

Stat Med. 2017 May 10;36(10):1599-1618. doi: 10.1002/sim.7229. Epub 2017 Jan 23.

PMID:
28114748
14.

Strict blood pressure control associates with decreased mortality risk by APOL1 genotype.

Ku E, Lipkowitz MS, Appel LJ, Parsa A, Gassman J, Glidden DV, Smogorzewski M, Hsu CY.

Kidney Int. 2017 Feb;91(2):443-450. doi: 10.1016/j.kint.2016.09.033. Epub 2016 Dec 4.

15.

The Lorenz curve: a novel method for understanding viral load distribution at the population level.

Christopoulos KA, Hartogensis W, Glidden DV, Pilcher CD, Gandhi M, Geng EH.

AIDS. 2017 Jan 14;31(2):309-310. doi: 10.1097/QAD.0000000000001336.

16.

Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study.

Gandhi M, Glidden DV, Mayer K, Schechter M, Buchbinder S, Grinsztejn B, Hosek S, Casapia M, Guanira J, Bekker LG, Louie A, Horng H, Benet LZ, Liu A, Grant RM.

Lancet HIV. 2016 Nov;3(11):e521-e528. doi: 10.1016/S2352-3018(16)30153-9. Epub 2016 Aug 31.

17.

Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing.

Castillo-Mancilla J, Seifert S, Campbell K, Coleman S, McAllister K, Zheng JH, Gardner EM, Liu A, Glidden DV, Grant R, Hosek S, Wilson CM, Bushman LR, MaWhinney S, Anderson PL.

Antimicrob Agents Chemother. 2016 Oct 21;60(11):6692-6697. doi: 10.1128/AAC.01017-16. Print 2016 Nov.

18.

Pharmacology supports on-demand PrEP.

Glidden DV, Anderson PL, Grant RM.

Lancet HIV. 2016 Sep;3(9):e405-e406. doi: 10.1016/S2352-3018(16)30114-X. No abstract available.

19.

BP Control and Long-Term Risk of ESRD and Mortality.

Ku E, Gassman J, Appel LJ, Smogorzewski M, Sarnak MJ, Glidden DV, Bakris G, Gutiérrez OM, Hebert LA, Ix JH, Lea J, Lipkowitz MS, Norris K, Ploth D, Pogue VA, Rostand SG, Siew ED, Sika M, Tisher CC, Toto R, Wright JT Jr, Wyatt C, Hsu CY.

J Am Soc Nephrol. 2017 Feb;28(2):671-677. doi: 10.1681/ASN.2016030326. Epub 2016 Aug 11.

20.

Impact of genetic variants on the upstream efficacy of renin-angiotensin system inhibitors for the prevention of atrial fibrillation.

Roberts JD, Dewland TA, Glidden DV, Hoffmann TJ, Arking DE, Chen LY, Psaty BM, Olgin JE, Alonso A, Heckbert SR, Marcus GM.

Am Heart J. 2016 May;175:9-17. doi: 10.1016/j.ahj.2016.02.002. Epub 2016 Feb 13.

21.

PrEP adherence among trans women in Brazil-access needed for this key population - Authors' reply.

Sevelius J, Deutsch MB, Glidden DV, Grant RM.

Lancet HIV. 2016 May;3(5):e200-1. doi: 10.1016/S2352-3018(16)30023-6. No abstract available.

PMID:
27126486
22.

The Effect of Depressive Symptoms on Adherence to Daily Oral PrEP in Men who have Sex with Men and Transgender Women: A Marginal Structural Model Analysis of The iPrEx OLE Study.

Mehrotra ML, Glidden DV, McMahan V, Amico KR, Hosek S, Defechereux P, Mayer KH, Veloso VG, Bekker LG, Avelino-Silva VI, Schechter M, Grant RM.

AIDS Behav. 2016 Jul;20(7):1527-34. doi: 10.1007/s10461-016-1415-9.

23.

HIV moments and pre-exposure prophylaxis.

Grant RM, Glidden DV.

Lancet. 2016 Apr 9;387(10027):1507-8. doi: 10.1016/S0140-6736(16)30125-8. Epub 2016 Apr 7. No abstract available.

PMID:
27115970
24.

Contemporary Profile of Seizures in Neonates: A Prospective Cohort Study.

Glass HC, Shellhaas RA, Wusthoff CJ, Chang T, Abend NS, Chu CJ, Cilio MR, Glidden DV, Bonifacio SL, Massey S, Tsuchida TN, Silverstein FS, Soul JS; Neonatal Seizure Registry Study Group.

J Pediatr. 2016 Jul;174:98-103.e1. doi: 10.1016/j.jpeds.2016.03.035. Epub 2016 Apr 19.

25.

Height at First RRT and Mortality in Children.

Ku E, Fine RN, Hsu CY, McCulloch C, Glidden DV, Grimes B, Johansen KL.

Clin J Am Soc Nephrol. 2016 May 6;11(5):832-9. doi: 10.2215/CJN.08250815. Epub 2016 Mar 1.

26.

Symptoms, Side Effects and Adherence in the iPrEx Open-Label Extension.

Glidden DV, Amico KR, Liu AY, Hosek SG, Anderson PL, Buchbinder SP, McMahan V, Mayer KH, David B, Schechter M, Grinsztejn B, Guanira J, Grant RM.

Clin Infect Dis. 2016 May 1;62(9):1172-7. doi: 10.1093/cid/ciw022. Epub 2016 Jan 20.

27.

Patient-reported factors associated with reengagement among HIV-infected patients disengaged from care in East Africa.

Camlin CS, Neilands TB, Odeny TA, Lyamuya R, Nakiwogga-Muwanga A, Diero L, Bwana M, Braitstein P, Somi G, Kambugu A, Bukusi EA, Glidden DV, Wools-Kaloustian KK, Wenger M, Geng EH; East Africa International Epidemiologic Databases to Evaluate AIDS (EA-IeDEA) Consortium.

AIDS. 2016 Jan 28;30(3):495-502. doi: 10.1097/QAD.0000000000000931.

28.

Crude incidence in two-phase designs in the presence of competing risks.

Rebora P, Antolini L, Glidden DV, Valsecchi MG.

BMC Med Res Methodol. 2016 Jan 11;16:5. doi: 10.1186/s12874-015-0103-1.

29.

Retention in Care and Patient-Reported Reasons for Undocumented Transfer or Stopping Care Among HIV-Infected Patients on Antiretroviral Therapy in Eastern Africa: Application of a Sampling-Based Approach.

Geng EH, Odeny TA, Lyamuya R, Nakiwogga-Muwanga A, Diero L, Bwana M, Braitstein P, Somi G, Kambugu A, Bukusi E, Wenger M, Neilands TB, Glidden DV, Wools-Kaloustian K, Yiannoutsos C, Martin J.

Clin Infect Dis. 2016 Apr 1;62(7):935-944. doi: 10.1093/cid/civ1004. Epub 2015 Dec 17.

30.

Association of Frailty based on self-reported physical function with directly measured kidney function and mortality.

Delgado C, Grimes BA, Glidden DV, Shlipak M, Sarnak MJ, Johansen KL.

BMC Nephrol. 2015 Dec 9;16:203. doi: 10.1186/s12882-015-0202-6.

31.

HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial.

Deutsch MB, Glidden DV, Sevelius J, Keatley J, McMahan V, Guanira J, Kallas EG, Chariyalertsak S, Grant RM; iPrEx investigators.

Lancet HIV. 2015 Dec;2(12):e512-9. doi: 10.1016/S2352-3018(15)00206-4. Epub 2015 Nov 6.

32.

Statistical issues in trials of preexposure prophylaxis.

Dunn DT, Glidden DV.

Curr Opin HIV AIDS. 2016 Jan;11(1):116-21. doi: 10.1097/COH.0000000000000218. Review.

33.

Estimation of mortality among HIV-infected people on antiretroviral treatment in East Africa: a sampling based approach in an observational, multisite, cohort study.

Geng EH, Odeny TA, Lyamuya RE, Nakiwogga-Muwanga A, Diero L, Bwana M, Muyindike W, Braitstein P, Somi GR, Kambugu A, Bukusi EA, Wenger M, Wools-Kaloustian KK, Glidden DV, Yiannoutsos CT, Martin JN.

Lancet HIV. 2015 Mar;2(3):e107-16. doi: 10.1016/S2352-3018(15)00002-8. Epub 2015 Jan 28.

34.

Evidence for α-synuclein prions causing multiple system atrophy in humans with parkinsonism.

Prusiner SB, Woerman AL, Mordes DA, Watts JC, Rampersaud R, Berry DB, Patel S, Oehler A, Lowe JK, Kravitz SN, Geschwind DH, Glidden DV, Halliday GM, Middleton LT, Gentleman SM, Grinberg LT, Giles K.

Proc Natl Acad Sci U S A. 2015 Sep 22;112(38):E5308-17. doi: 10.1073/pnas.1514475112. Epub 2015 Aug 31.

35.

The Kynurenine Pathway of Tryptophan Catabolism and AIDS-Associated Kaposi Sarcoma in Africa.

Byakwaga H, Hunt PW, Laker-Oketta M, Glidden DV, Huang Y, Bwana BM, Mocello AR, Bennett J, Walusansa V, Dollard SC, Bangsberg DR, Mbidde EK, Martin JN.

J Acquir Immune Defic Syndr. 2015 Nov 1;70(3):296-303. doi: 10.1097/QAI.0000000000000747.

36.

Cellular immune correlates analysis of an HIV-1 preexposure prophylaxis trial.

Kuebler PJ, Mehrotra ML, McConnell JJ, Holditch SJ, Shaw BI, Tarosso LF, Leadabrand KS, Milush JM, York VA, Raposo RA, Cheng RG, Eriksson EM, McMahan V, Glidden DV, Shiboski S, Grant RM, Nixon DF, Kallás EG.

Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):8379-84. doi: 10.1073/pnas.1501443112. Epub 2015 Jun 22.

37.

Depression and Oral FTC/TDF Pre-exposure Prophylaxis (PrEP) Among Men and Transgender Women Who Have Sex With Men (MSM/TGW).

Defechereux PA, Mehrotra M, Liu AY, McMahan VM, Glidden DV, Mayer KH, Vargas L, Amico KR, Chodacki P, Fernandez T, Avelino-Silva VI, Burns D, Grant RM; iPrEx Study Team.

AIDS Behav. 2016 Jul;20(7):1478-88. doi: 10.1007/s10461-015-1082-2.

38.

Association of Body Mass Index with Patient-Centered Outcomes in Children with ESRD.

Ku E, Glidden DV, Hsu CY, Portale AA, Grimes B, Johansen KL.

J Am Soc Nephrol. 2016 Feb;27(2):551-8. doi: 10.1681/ASN.2015010008. Epub 2015 Jun 8.

39.

Impaired cognitive performance in premature newborns with two or more surgeries prior to term-equivalent age.

Gano D, Andersen SK, Glass HC, Rogers EE, Glidden DV, Barkovich AJ, Ferriero DM.

Pediatr Res. 2015 Sep;78(3):323-9. doi: 10.1038/pr.2015.106. Epub 2015 May 28.

40.

Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial.

Mulligan K, Glidden DV, Anderson PL, Liu A, McMahan V, Gonzales P, Ramirez-Cardich ME, Namwongprom S, Chodacki P, de Mendonca LM, Wang F, Lama JR, Chariyalertsak S, Guanira JV, Buchbinder S, Bekker LG, Schechter M, Veloso VG, Grant RM; Preexposure Prophylaxis Initiative Study Team.

Clin Infect Dis. 2015 Aug 15;61(4):572-80. doi: 10.1093/cid/civ324. Epub 2015 Apr 23.

41.

Strong Correlation Between Concentrations of Tenofovir (TFV) Emtricitabine (FTC) in Hair and TFV Diphosphate and FTC Triphosphate in Dried Blood Spots in the iPrEx Open Label Extension: Implications for Pre-exposure Prophylaxis Adherence Monitoring.

Gandhi M, Glidden DV, Liu A, Anderson PL, Horng H, Defechereux P, Guanira JV, Grinsztejn B, Chariyalertsak S, Bekker LG, Grant RM; iPrEx Study Team.

J Infect Dis. 2015 Nov 1;212(9):1402-6. doi: 10.1093/infdis/jiv239. Epub 2015 Apr 20.

42.

Association between strict blood pressure control during chronic kidney disease and lower mortality after onset of end-stage renal disease.

Ku E, Glidden DV, Johansen KL, Sarnak M, Tighiouart H, Grimes B, Hsu CY.

Kidney Int. 2015 May;87(5):1055-60. doi: 10.1038/ki.2014.376. Epub 2014 Dec 10.

43.

Dose response for starting and stopping HIV preexposure prophylaxis for men who have sex with men.

Seifert SM, Glidden DV, Meditz AL, Castillo-Mancilla JR, Gardner EM, Predhomme JA, Rower C, Klein B, Kerr BJ, Guida LA, Zheng JH, Bushman LR, Anderson PL.

Clin Infect Dis. 2015 Mar 1;60(5):804-10. doi: 10.1093/cid/ciu916. Epub 2014 Nov 18. Erratum in: Clin Infect Dis. 2015 Jul 1;61(1):143.

44.

Telomere length and the risk of atrial fibrillation: insights into the role of biological versus chronological aging.

Roberts JD, Dewland TA, Longoria J, Fitzpatrick AL, Ziv E, Hu D, Lin J, Glidden DV, Psaty BM, Burchard EG, Blackburn EH, Olgin JE, Heckbert SR, Marcus GM.

Circ Arrhythm Electrophysiol. 2014 Dec;7(6):1026-32. doi: 10.1161/CIRCEP.114.001781. Epub 2014 Nov 8.

45.

Reply to Boyd et al.

Solomon MM, Mayer KH, Glidden DV, Guanira JV, Grant RM.

Clin Infect Dis. 2015 Jan 15;60(2):327. doi: 10.1093/cid/ciu814. Epub 2014 Oct 16. No abstract available.

46.

Diminished white matter injury over time in a cohort of premature newborns.

Gano D, Andersen SK, Partridge JC, Bonifacio SL, Xu D, Glidden DV, Ferriero DM, Barkovich AJ, Glass HC.

J Pediatr. 2015 Jan;166(1):39-43. doi: 10.1016/j.jpeds.2014.09.009. Epub 2014 Oct 12.

47.

Patterns and correlates of PrEP drug detection among MSM and transgender women in the Global iPrEx Study.

Liu A, Glidden DV, Anderson PL, Amico KR, McMahan V, Mehrotra M, Lama JR, MacRae J, Hinojosa JC, Montoya O, Veloso VG, Schechter M, Kallas EG, Chariyalerstak S, Bekker LG, Mayer K, Buchbinder S, Grant R; iPrEx Study team.

J Acquir Immune Defic Syndr. 2014 Dec 15;67(5):528-37. doi: 10.1097/QAI.0000000000000351.

48.

Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study.

Grant RM, Anderson PL, McMahan V, Liu A, Amico KR, Mehrotra M, Hosek S, Mosquera C, Casapia M, Montoya O, Buchbinder S, Veloso VG, Mayer K, Chariyalertsak S, Bekker LG, Kallas EG, Schechter M, Guanira J, Bushman L, Burns DN, Rooney JF, Glidden DV; iPrEx study team.

Lancet Infect Dis. 2014 Sep;14(9):820-9. doi: 10.1016/S1473-3099(14)70847-3. Epub 2014 Jul 22.

PMID:
25065857
49.

Healthcare utilization and clinical outcomes after catheter ablation of atrial flutter.

Dewland TA, Glidden DV, Marcus GM.

PLoS One. 2014 Jul 1;9(7):e100509. doi: 10.1371/journal.pone.0100509. eCollection 2014.

50.

Syphilis predicts HIV incidence among men and transgender women who have sex with men in a preexposure prophylaxis trial.

Solomon MM, Mayer KH, Glidden DV, Liu AY, McMahan VM, Guanira JV, Chariyalertsak S, Fernandez T, Grant RM; iPrEx Study Team.

Clin Infect Dis. 2014 Oct;59(7):1020-6. doi: 10.1093/cid/ciu450. Epub 2014 Jun 13.

Supplemental Content

Loading ...
Support Center